The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.
Article obtained from Photonics RSS Feed.
Drug discovery and development company Eikon Therapeutics closed $148 million Series A financing and appointed Roger Perlmutter CEO. Eikon’s drug discovery platform uses superresolution microscopy, an approach that elucidates the behavior of proteins in live cells. Superresolution microscopy was developed by Eric Betzig and collaborators, who received the Nobel Prize in chemistry in 2014. The company’s Scientific Advisory Board (SAB) includes Betzig, who is a co-founder of Eikon Therapeutics.
Perlmutter was previously an executive vice president at Merck and president of Merck Research Laboratories. Under his leadership, Merck received more than 100 regulatory approvals for its medicines and vaccines globally, including those…